Growth Metrics

Adma Biologics (ADMA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $36.4 million.

  • Adma Biologics' Consolidated Net Income rose 144.53% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 20741.36%. This contributed to the annual value of $197.7 million for FY2024, which is 80000.0% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Consolidated Net Income is $36.4 million, which was up 144.53% from $34.2 million recorded in Q2 2025.
  • Adma Biologics' 5-year Consolidated Net Income high stood at $111.9 million for Q4 2024, and its period low was -$18.8 million during Q2 2021.
  • For the 5-year period, Adma Biologics' Consolidated Net Income averaged around $7.2 million, with its median value being -$6.8 million (2023).
  • In the last 5 years, Adma Biologics' Consolidated Net Income crashed by 4962.75% in 2023 and then skyrocketed by 129996.1% in 2024.
  • Adma Biologics' Consolidated Net Income (Quarter) stood at -$16.5 million in 2021, then grew by 28.55% to -$11.8 million in 2022, then crashed by 49.63% to -$17.6 million in 2023, then surged by 734.15% to $111.9 million in 2024, then plummeted by 67.44% to $36.4 million in 2025.
  • Its Consolidated Net Income was $36.4 million in Q3 2025, compared to $34.2 million in Q2 2025 and $26.9 million in Q1 2025.